Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPASS: Gefitinib vs Carboplatin/Paclitaxel in NSCLC
NCT00322452Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2006; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00322452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322452.